Amoy Diagnostics Co., Ltd.

Equities

300685

CNE1000034D3

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
21.55 ^CNY	+2.13%		+2.13%	-1.96%

Apr. 22	Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 15	Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.

July 04, 2022 at 05:22 am EDT

From April 1, 2022 to June 30, 2022, the company has repurchased 411,400 shares, representing 0.1% for CNY 18.18 million. With this, the company has completed the repurchase of 694,800 shares, representing 0.17% for CNY 32.12 million under the buyback announced on February 14, 2022.

Latest news about Amoy Diagnostics Co., Ltd.

Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
Amoy Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.	Apr. 01	CI
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component A Share Index	Dec. 11	CI
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index	Dec. 11	CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-23	CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-31	CI
Amoy Diagnostics to Collaborate with AstraZeneca Unit for Ovarian Cancer Companion Diagnostic in China	23-07-26	MT
Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023	23-05-16	CI
Amoy Diagnostics Co., Ltd. Approves Final Dividend for 2022	23-05-12	CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-21	CI
Amoy Diagnostics Co., Ltd. Proposes Final Cash Dividend for the Year 2022	23-04-17	CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. and Precision Medicine Asia Co., Ltd. Announces the Japanese Ministry of Health, Labour and Welfare Approval in Japan as a Companion Diagnostic for Ret Fusion-Positive NSCLC	23-03-27	CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.	23-02-14	CI
Amoy Diagnostics Co., Ltd.'s Equity Buyback announced on February 13, 2023 has expired with 3,943,726 shares, representing 1% for CNY 112.01 million.	23-02-12	CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.	23-01-03	CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.	22-10-10	CI
Alercell® to Distribute Amoydx® Ros1 Gene Fusion Detection Kit	22-08-08	CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-29	CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.	22-07-04	CI
Amoy Diagnostics Co., Ltd. Announces Dividend, Payable on May 31, 2022	22-05-25	CI
Amoy Diagnostics Co., Ltd. Approves Dividend for 2021	22-05-12	CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-20	CI

Chart Amoy Diagnostics Co., Ltd.

Duration

Period

More charts

Company Profile

Amoy Diagnostics Co Ltd is a pharmaceutical company engaged in research, development, production and sales of molecular diagnostic products. The Company provides testing reagents and testing services for tumor diagnosis. The Companyâs testing reagent products include ADx-ARMS product line for tumor tissue specimen detection, Super-ARMS product line for liquid biopsy, the NGS product line and the FISH product line. The products are used for the detection of non-small cell lung cancer, colorectal cancer, thyroid cancer, melanoma and other malignant tumors. The Company also provides data software to capture and analyze gene sequencing data. The Company provides testing services through its own medical testing institutions, including lung cancer testing, colorectal cancer testing and breast cancer testing.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-13 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Amoy Diagnostics Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.55 CNY

Average target price

29.55 CNY

Spread / Average Target

+37.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
AMOY DIAGNOSTICS CO., LTD.	-1.96%	1.15B
BIOMÉRIEUX	+0.89%	12.59B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-10.29%	7.42B
DIASORIN S.P.A.	+1.78%	5.35B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.16%	4.51B
LANTHEUS HOLDINGS, INC.	+5.74%	4.47B
10X GENOMICS, INC.	-50.70%	3.21B
ANDON HEALTH CO., LTD.	+12.21%	2.71B
VITROLIFE AB	-16.13%	1.96B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.50%	1.73B

Diagnostic & Testing Substances